BIMI International Medical Inc. (BIMI) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBIMI International Medical Inc. (BIMI) trades at $0.0001. BIMI International Medical Inc. operates in the retail and wholesale distribution of medical devices, pharmaceuticals, and healthcare products within the People's Republic of China. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for BIMI: BIMI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
BIMI International Medical Inc. (BIMI) Healthcare & Pipeline Overview
BIMI International Medical Inc. focuses on the distribution of medical devices, pharmaceuticals, and healthcare products in China, operating through wholesale and retail channels. The company offers a range of products, including pharmaceuticals, medical devices, and traditional Chinese medicines, primarily serving the Southwest region of China.
What Is the Investment Thesis for BIMI?
BIMI International Medical Inc. presents a speculative investment opportunity within the Chinese healthcare market, contingent on successful execution of its distribution and service strategies. The company's diverse operations across wholesale pharmaceuticals, medical devices, retail pharmacies, and medical services provide multiple revenue streams. However, its negative profit margin of -189.3% raises concerns about its financial stability. Growth catalysts include expanding its distribution network and enhancing its medical service offerings. Key risks include navigating regulatory complexities in the Chinese healthcare market and achieving profitability. Investors should closely monitor the company's ability to improve its financial performance and capitalize on market opportunities.
Based on FMP financials and quantitative analysis
BIMI Key Highlights
BIMI operates in four segments: Wholesale Pharmaceuticals, Wholesale Medical Devices, Medical Services, and Retail Pharmacies, providing diversification.
- Distributes Stryker spinal products and Olympus endoscopes, indicating partnerships with established medical device manufacturers.
- Operates retail pharmacies under the Lijiantang Pharmacy brand, offering a range of healthcare products.
- Profit margin of -189.3% indicates significant financial challenges.
- Market capitalization of $0.00B reflects its small size and potential volatility.
Who Are BIMI's Competitors?
BIMI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| RDGT Ridgetech Inc. | $0.87 | +2.81% | — | |
| ACH Accendra Health, Inc. | $0.51 | -9.43% | $38.7M | — |
| PBH Prestige Consumer Healthcare Inc. | $45.26 | +1.09% | $2.14B | — |
| GRDN Guardian Pharmacy Services, Inc. | $42.38 | +3.77% | $2.68B | — |
| HSIC Henry Schein, Inc. | $84.88 | -0.06% | $9.67B | — |
| CAH Cardinal Health, Inc. | $228.30 | -0.78% | $53.5B | — |
| COR Cencora, Inc. | $309.05 | -0.24% | $60.1B | — |
| MCK McKesson Corporation | $902.28 | +0.38% | $106B | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BIMI's Key Strengths?
Established distribution network in Southwest China.
- Partnerships with reputable medical device manufacturers.
- Diverse product portfolio.
- Presence in both wholesale and retail channels.
What Are BIMI's Weaknesses?
Negative profit margin.
- Limited geographic reach beyond Southwest China.
- Dependence on third-party suppliers.
- Small market capitalization.
What Are the Key Risks for BIMI?
Financial-distress signal — its Altman Z-Score of -3.54 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory changes in the Chinese healthcare market could impact operations and profitability.
- Intense competition from established domestic and international players.
- Fluctuations in currency exchange rates could affect financial performance.
- The company's negative profit margin poses a risk to its long-term financial stability.
- Limited liquidity due to OTC Other market trading.
What Are BIMI's Competitive Advantages?
- Established distribution network in the Southwest region of China.
- Partnerships with established medical device manufacturers like Stryker and Olympus.
- Retail pharmacy network under the Lijiantang Pharmacy brand.
- Diverse product portfolio including medical devices, pharmaceuticals, and traditional Chinese medicines.
What Does BIMI Do?
BIMI International Medical Inc., originally incorporated in 2000 and based in Chongqing, China, is a multifaceted healthcare company engaged in the distribution of medical devices, pharmaceuticals, and other healthcare products. The company operates through four key segments: Wholesale Pharmaceuticals, Wholesale Medical Devices, Medical Services, and Retail Pharmacies. BIMI distributes a variety of products, including Stryker spinal products, Olympus endoscopes, imported imaging products, and diagnostic imaging equipment, targeting drug stores, private clinics, pharmaceutical dealers, and hospitals, particularly in the Southwest region of China. In addition to distributing branded medical equipment, BIMI also deals in generic drugs, Chinese herbal medicine, biochemical drugs, raw ingredients for pharmaceutical products, antibiotics, cardiovascular drugs, and anti-obesity medicines. The company's retail operations are conducted under the Lijiantang Pharmacy brand, offering prescription and over-the-counter drugs, nutritional supplements, health foods, sundry products, traditional Chinese medicines, personal and family care products, medical devices, and miscellaneous items. BIMI also provides medical services through its hospitals and IT research and development services. The company changed its name from BOQI International Medical Inc. to BIMI International Medical Inc. in June 2021, reflecting its ongoing evolution and strategic focus within the healthcare sector.
What Products and Services Does BIMI Offer?
- Wholesale distribution of medical devices.
- Wholesale distribution of pharmaceuticals.
- Operation of retail pharmacies under the Lijiantang Pharmacy brand.
- Provision of medical services through hospitals.
- Distribution of Stryker spinal products and Olympus endoscopes.
- Distribution of generic drugs and traditional Chinese medicines.
- IT research and development services.
How Does BIMI Make Money?
- Generates revenue through the wholesale distribution of medical devices and pharmaceuticals to hospitals, clinics, and pharmacies.
- Earns revenue from the retail sale of prescription and over-the-counter drugs, health foods, and medical devices through its Lijiantang Pharmacy stores.
- Provides medical services in hospitals, generating revenue from patient care and related services.
What Industry Does BIMI Operate In?
BIMI International Medical Inc. operates within the rapidly growing Chinese healthcare market, driven by increasing healthcare expenditure and an aging population. The market is characterized by intense competition among domestic and international players. BIMI's focus on distributing medical devices and pharmaceuticals positions it within a critical segment of the healthcare supply chain. The company faces competition from established distributors and retailers, including ADYX, BGMD, CFRXQ, DMKPQ, and EFTR. Success depends on navigating regulatory hurdles, building strong relationships with suppliers and customers, and adapting to evolving market trends.
Who Are BIMI's Key Customers?
- Drug stores in the People's Republic of China.
- Private clinics in the People's Republic of China.
- Pharmaceutical dealers in the People's Republic of China.
- Hospitals in the People's Republic of China.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
BIMI International Medical Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -3.54 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on assets is -62.7%, showing how much profit it generates from its asset base. A current ratio of 0.92 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
BIMI International Medical Inc. operates in the Healthcare sector. It is headquartered in New York, US. The company is led by CEO Tiewei Song. BIMI has traded publicly since 2006.
Insider Activity
12 transactions · 0 purchases, 2 sales, 10 other transactions · 3 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
BIMI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
BIMI Latest News
No recent news available for BIMI.
BIMI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BIMI.
Price Targets
Wall Street price target analysis for BIMI.
BIMI MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BIMI; grades run from A+ (80-100) to F (below 30).
Leadership: Tiewei Song
CEO
Tiewei Song serves as the CEO of BIMI International Medical Inc., overseeing the company's strategic direction and operations. Information regarding Mr. As CEO, he is responsible for managing the company's 296 employees and driving its growth in the Chinese healthcare market.
Track Record: Due to limited information available, it is not possible to provide a comprehensive assessment of Tiewei Song's track record. His leadership is focused on navigating the complexities of the Chinese healthcare market and expanding BIMI's presence in the distribution of medical devices and pharmaceuticals.
BIMI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that BIMI International Medical Inc. may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited reporting requirements and may be subject to greater risks due to less stringent regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investors should exercise caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Check for any regulatory actions or legal disputes.
- Monitor trading volume and price volatility.
- Consult with a financial advisor.
- Distribution agreements with established medical device manufacturers.
- Operation of retail pharmacies under the Lijiantang Pharmacy brand.
- Presence in the Chinese healthcare market since 2000.
- Company size of 296 employees.
- Physical headquarters located in Chongqing, China.
BIMI International Medical Inc. Healthcare Stock: Key Questions Answered
What do analysts say about BIMI stock?
As of March 17, 2026, there is no available analyst coverage or consensus on BIMI International Medical Inc. due to its OTC listing and small market capitalization.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited information available on CEO Tiewei Song's background and track record.
- Financial data based on available information and may not be fully comprehensive.
- OTC market investments carry higher risks than exchange-listed stocks.